Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays ...
Polyrizon Ltd. (NASDAQ: PLRZ) is a development-stage biotech focused on intranasal care using medical device hydrogels formulated as nasal sprays. Based in Ra’anana, Israel, the company’s core concept is to “Capture & Contain (C&C)” substances that enter the nasal cavity, forming a protective barrier intended to reduce the likelihood that ...Polyrizon Ltd. (NASDAQ: PLRZ) is a development-stage biotech focused on intranasal care using medical device hydrogels formulated as nasal sprays. Based in Ra’anana, Israel, the company’s core concept is to “Capture & Contain (C&C)” substances that enter the nasal cavity, forming a protective barrier intended to reduce the likelihood that viruses and allergens adhere to nasal epithelial tissue. This positioning targets common routes of exposure for respiratory pathogens and inhaled allergens, aligning the company’s R&D and product strategy around preventive intranasal interventions.
From a product and pipeline perspective, Polyrizon’s publicly described programs include PL-14 (directed at blocking nasal allergies), PL-15 (aimed at COVID-19), and PL-16 (intended for influenza prevention). These programs reflect a common platform approach—hydrogel nasal delivery with the same protective-barrier objective—while differentiating by target indication. Commercially, the company’s ambition is to transform its lab-born intranasal hydrogel vision into scalable products, which typically implies substantial investment in formulation work, preclinical/clinical studies, regulatory pathways, manufacturing readiness, and eventual commercialization capabilities.
In terms of resources and scale, the provided dataset lists full-time employees as 0, indicating the company operates with a very small core team or that headcount data may not be fully populated in the source. Regardless, as a development-stage company, expected cost structure would be dominated by R&D spending (formulation development, clinical/regulatory work, quality systems, and fielding/scale-up planning). Publicly available financial metrics in the supplied data indicate limited revenue/operating profit performance in the TTM snapshot, consistent with early-stage development.
Financially, the dataset shows negative profitability indicators (e.g., negative returns and negative free cash flow measures) and a relatively high current ratio on a TTM basis, which is consistent with companies that have raised capital to fund development while still ramping operational scale. Cost and BOM (bill of materials) specifics for its hydrogel sprays are not provided in the supplied information; however, hydrogel medical-device manufacturing generally requires controlled raw-material sourcing, sterile/controlled manufacturing processes, and packaging suitable for nasal administration—factors that can influence unit economics once commercialization begins.
Key leadership is Tomer Izraeli, who serves as founder and CEO and has been associated with the company’s leadership since March 2020 (per the provided materials). As of the company’s incorporation in 2005 and its more recent Nasdaq listing (IPO in October 2024, per the provided context), Polyrizon’s near-term “wishes” and strategic priorities would likely center on clinical/regulatory progress for its indications, strengthening manufacturing and quality readiness for nasal hydrogel devices, and building commercial partnerships or go-to-market capability to support eventual product launches across allergy and respiratory-virus-related opportunities.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-3.3M
-115.9%
-1686.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-4.5M
-295.4%
-100.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
29.03x
+185.6%
0.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
